🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. [177Lu]Lu-XT117

    The First People's Hospital of Lianyungang

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  2. [68Ga]MLN6907

    Takeda

    Imaging of Solid Gastrointestinal Tumors

    phase 1 small molecule completed

    1 trial

  3. [^14C]-alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  4. agenT-797

    MiNK Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    1 trial

  5. darinaparsin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  6. idronoxil

    KAZIA THERAPEUTICS LTD

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 1 small molecule completed

    1 trial

  7. indibulin

    Alaunos Therapeutics

    Solid Tumors

    phase 1 small molecule active

    2 trials

  8. nesvacumab (REGN910/ SAR307746)

    Regeneron UK Limited

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  9. palifosfamide-tris

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  10. pd-1 and DC-NK cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  11. pd-1 and dc-cik cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  12. zanzalintinib

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  13. zimberelimab

    Arcus Biosciences

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  14. ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  15. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  16. Braftovi 50 mg hard capsules, Zelboraf 240 mg film-coated tablets, Encorafenib, Erbitux 5 mg/mL solution for infusion, PEMBROLIZUMAB, Braftovi 75 mg hard capsules, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Ribociclib, Ribociclib, NIVOLUMAB, Mektovi 15 mg film-coated tablets, Mektovi 15 mg film-coated tablets, Ribociclib

    Pfizer Australia Pty Ltd

    Solid tumors

    approved small molecule active

    1 trial

  17. Dexamethasone 4 mg tablets, Dexamethasone Phosphate 4 mg/ml Solution for Injection

    Disc Medicine

    Solid tumors

    approved small molecule active

    1 trial

  18. Durvalumab

    AstraZeneca

    Solid Tumor

    approved small molecule completed

    1 trial

  19. GAVRETO ®(pralsetinib) capsules

    RIGEL PHARMACEUTICALS INC

    Patients with advanced or metastatic solid tumors

    approved small molecule active

    1 trial

  20. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial

  21. 18F-FDG

    The First People's Hospital of Lianyungang

    Tumor, Solid

    other completed

    1 trial

  22. 89Zr-KN035

    The First People's Hospital of Lianyungang

    Solid Tumor, Adult

    other active

    1 trial

  23. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Refractory Solid Tumors

    small molecule terminated

    1 trial

  24. Anti-HER2 CAR-T cells

    The First People's Hospital of Lianyungang

    HER2-positive Advanced Malignant Solid Tumors

    mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources